ArticleAnnals of clinical and translational neurology2017
Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis.
Article in Annals of clinical and translational neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.Therapeutic advances in neurological disorders · 2023Article
- Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.Psychopharmacology · 2022Review
- Smouldering multiple sclerosis: the 'real MS'.Therapeutic advances in neurological disorders · 2022Review
- Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.Therapeutic advances in neurological disorders · 2021Article
- Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement?Frontiers in neurology · 2020Article
- Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations.Neurology and therapy · 2019Review
- Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2018Article
- Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?Journal of neurology, neurosurgery, and psychiatry · 2018Article
- Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.Journal of neurology · 2018Article
- Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rebound disease following cessation of disease modifying treatment (DMT) has been reported in people with both relapsing and progressive multiple sclerosis (pwRMS, pwPMS) questioning strict separation between these two phenotypes. While licensed DMT is available for pwRMS to counter rebound disease, no such option exists for pwPMS. We report on a pwPMS who developed rebound disease, with 45 Gadolinium-enhancing lesions on T
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.